Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + sunitinib
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of docetaxel, a taxane chemotherapy agent that disrupts the microtubule network essential for mitotic and interphase cellular functions, leading to cell death, and sunitinib, an oral multi-targeted tyrosine kinase inhibitor that works by inhibiting multiple receptor tyrosine kinases involved in tumor growth, pathologic angiogenesis, and metastatic progression. When combined, these agents have shown enhanced antitumor activity in preclinical models compared to single agents.
02
Targets
PDGFR (PDGFR family)TUBB (Tubulin (alpha and beta subunits))VEGFR (VEGFR family)
Beyond the preview
Go deeper on docetaxel + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + sunitinib.